The role of pharmacogenetics and advances in gene therapy in the treatment of diabetic retinopathy

Aniruddha Agarwal, Sally A. Ingham, Keegan A. Harkins, DIana V. Do, Quan Dong Nguyen

Research output: Contribution to journalReview article

10 Scopus citations

Abstract

Diabetic retinopathy (DR) and its complications such as diabetic macular edema continue to remain a major cause for legal blindness in the developed world. While the introduction of anti-tVEGF agents has significantly improved visual outcomes of patients with DR, unpredictable response, largely due to genetic polymorphisms, appears to be a challenge with this therapy. With advances in identification of various genetic biomarkers, novel therapeutic strategies consisting of gene transfer are being developed and tested for patients with DR. Application of pharmacogenetic principles appears to be a promising futuristic strategy to attenuate diabetes-mediated retinal vasculopathy. In this comprehensive review, data from recent studies in the field of pharmacogenomics for the treatment of DR have been provided.

Original languageEnglish (US)
Pages (from-to)309-320
Number of pages12
JournalPharmacogenomics
Volume17
Issue number3
DOIs
StatePublished - Feb 2016

Keywords

  • HLA
  • VEGF mutation
  • diabetic retinopathy
  • gene therapy
  • genomic markers
  • linkage
  • mutation
  • pharmacogenomics
  • polymorphism
  • viral vectors

ASJC Scopus subject areas

  • Molecular Medicine
  • Genetics
  • Pharmacology

Fingerprint Dive into the research topics of 'The role of pharmacogenetics and advances in gene therapy in the treatment of diabetic retinopathy'. Together they form a unique fingerprint.

  • Cite this

    Agarwal, A., Ingham, S. A., Harkins, K. A., Do, DI. V., & Nguyen, Q. D. (2016). The role of pharmacogenetics and advances in gene therapy in the treatment of diabetic retinopathy. Pharmacogenomics, 17(3), 309-320. https://doi.org/10.2217/pgs.15.173